Aldeyra Therapeutics Inc

NASDAQ:ALDX   4:00:00 PM EDT
6.20
-0.26 (-4.03%)
6:54:36 PM EDT: $6.10 -0.10 (-1.61%)
Regulatory, Earnings Announcements

Aldeyra Therapeutics Reports Q3 2022 Results

Published: 11/10/2022 12:40 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Reports Third-quarter 2022 Financial Results and Recent Corporate Highlights.
Aldeyra Therapeutics Inc- NDA Submission of Reproxalap for the Treatment of Dry Eye Disease on Schedule for the Fourth Quarter of 2022.
Aldeyra Therapeutics - Op-line Results From Phase 2 Clinical Trial of Oral Rasp Modulator Adx-629 in Acute Alcoholic Hepatitis Expected by End of 2022.
Aldeyra Therapeutics Inc- Top-line Results From the Phase 2 Clinical Trial of Adx-2191 in Retinitis Pigmentosa Expected in the First Half of 2023.
Aldeyra Therapeutics Inc- Cash, Cash Equivalents, and Marketable Securities Exceeding $185 Million As of September 30, 2022.
Aldeyra Therapeutics Inc - Qtrly Loss per Share $0.25.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.66

More details on our Analysts Page.